Recruiting
Hepatocellular carcinoma
RecruitingA Phase II Study of Cadonilimab Plus Lenvatinib Versus Lenvatinib in Advanced Hepatocellular Carcinoma After Atezolizumab/Bevacizumab Progression
Registered drugNo placebo
A Phase II Study of Cadonilimab Plus Lenvatinib Versus Lenvatinib in Advanced Hepatocellular Carcinoma After Atezolizumab/Bevacizumab Progression
Registered drugNo placebo
- Disease:Hepatocellular carcinoma
- Substances:Lenvatinib
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Lenvatinib
- Sponsor:Akeso Biopharma Co. Ltd.



